Aquestive Therapeutics (AQST) News Today → How to Make 100X on the AI Boom (From InvestorPlace) (Ad) Free AQST Stock Alerts $3.20 -0.07 (-2.14%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 7:48 AM | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Raised to "Strong-Buy" at Leerink PartnrsLeerink Partnrs raised shares of Aquestive Therapeutics to a "strong-buy" rating in a report on Friday.May 13 at 10:05 PM | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Large Growth in Short InterestAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) was the recipient of a large increase in short interest in April. As of April 30th, there was short interest totalling 5,270,000 shares, an increase of 31.4% from the April 15th total of 4,010,000 shares. Based on an average daily trading volume, of 2,810,000 shares, the days-to-cover ratio is presently 1.9 days.May 13 at 1:48 AM | americanbankingnews.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $8.00 Consensus PT from BrokeragesMay 12 at 4:30 AM | americanbankingnews.comAquestive Therapeutics (NASDAQ:AQST) Earns "Buy" Rating from HC WainwrightMay 12 at 4:30 AM | americanbankingnews.comSVB Leerink Initiates Coverage on Aquestive Therapeutics (NASDAQ:AQST)May 10, 2024 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of "Buy" by AnalystsAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has received a consensus rating of "Buy" from the six research firms that are currently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price tMay 10, 2024 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Earns Outperform Rating from Analysts at SVB LeerinkSVB Leerink began coverage on Aquestive Therapeutics in a research report on Friday. They issued an "outperform" rating and a $8.00 price target on the stock.May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Aquestive Therapeutics Amid Solid Finances and Promising Anaphylm™ ProspectsMay 9, 2024 | finance.yahoo.comAquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This YearMay 9, 2024 | finance.yahoo.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call TranscriptMay 9, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Aquestive Therapeutics (NASDAQ:AQST)HC Wainwright reissued a "buy" rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a report on Thursday.May 9, 2024 | globenewswire.comAquestive Therapeutics to Participate in The Citizens JMP Life Sciences ConferenceMay 9, 2024 | finance.yahoo.comAquestive Therapeutics Inc (AQST) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Aquestive Therapeutics (AQST) and Inspire Medical Systems (INSP)May 8, 2024 | wsj.comAquestive Therapeutics Inc.May 7, 2024 | investorplace.comAQST Stock Earnings: Aquestive Therapeutics Misses EPS, Misses Revenue for Q1 2024May 7, 2024 | msn.comAquestive Therapeutics GAAP EPS of -$0.17, revenue of $12.05MMay 7, 2024 | globenewswire.comAquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 5, 2024 | americanbankingnews.comAquestive Therapeutics (AQST) Scheduled to Post Quarterly Earnings on TuesdayApril 30, 2024 | markets.businessinsider.comAquestive Therapeutics Earns Buy Rating on Libervant’s Pediatric Approval and Anaphylm’s Market PotentialApril 30, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Aquestive Therapeutics (NASDAQ:AQST)HC Wainwright reaffirmed a "buy" rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a report on Tuesday.April 29, 2024 | msn.comAquestive stock falls amid Libervant approval, Anaphylm updateApril 29, 2024 | finance.yahoo.comAquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual FilmApril 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Aquestive Therapeutics Following FDA Approval and Growth ProspectsApril 26, 2024 | marketbeat.comShort Interest in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Rises By 76.7%Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 4,010,000 shares, a growth of 76.7% from the March 31st total of 2,270,000 shares. Based on an average trading volume of 2,450,000 shares, the days-to-cover ratio is presently 1.6 days.April 25, 2024 | finance.yahoo.comAquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ETApril 17, 2024 | investorplace.comComing FDA Approvals Could Send These 3 Drug Stocks SoaringApril 12, 2024 | globenewswire.comAquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of NeurologyApril 11, 2024 | msn.comPiper starts Aquestive at overweight, cites allergy reaction treatmentApril 11, 2024 | msn.comAquestive Therapeutics a new overweight at Piper on oral film productsApril 11, 2024 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Coverage Initiated by Analysts at Piper SandlerPiper Sandler initiated coverage on Aquestive Therapeutics in a research report on Thursday. They issued an "overweight" rating and a $10.00 price objective on the stock.April 5, 2024 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research report on Friday.March 28, 2024 | marketbeat.comRaymond James Begins Coverage on Aquestive Therapeutics (NASDAQ:AQST)Raymond James assumed coverage on Aquestive Therapeutics in a research report on Thursday. They set an "outperform" rating and a $7.00 price objective on the stock.March 25, 2024 | globenewswire.comAquestive Therapeutics Announces Closing of Underwritten Public Offering of Common StockMarch 25, 2024 | marketbeat.comLegato Capital Management LLC Makes New $688,000 Investment in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Legato Capital Management LLC acquired a new position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 340,564 shares of the company's stock, valued at approMarch 20, 2024 | msn.comAquestive Therapeutics slumps 13%, prices $75M offeringMarch 20, 2024 | investorplace.comWhy Is Aquestive Therapeutics (AQST) Stock Down 14% Today?March 20, 2024 | insidertrades.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Insider Alexander Mark Schobel Sells 50,000 SharesMarch 19, 2024 | globenewswire.comAquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common StockMarch 19, 2024 | finance.yahoo.comInsider Sell: Chief Innovation/Tech Officer Alexander Schobel Sells 50,000 Shares of Aquestive ...March 19, 2024 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Insider Sells $300,000.00 in StockAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) insider Alexander Mark Schobel sold 50,000 shares of the stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $6.00, for a total transaction of $300,000.00. Following the transaction, the insider now owns 984,476 shares in the company, valued at $5,906,856. The sale was disclosed in a filing with the SEC, which is available through this link.March 19, 2024 | globenewswire.comAquestive Therapeutics Announces Proposed Public Offering of Common StockMarch 18, 2024 | marketbeat.comHC Wainwright Increases Aquestive Therapeutics (NASDAQ:AQST) Price Target to $9.00HC Wainwright boosted their price objective on shares of Aquestive Therapeutics from $7.00 to $9.00 and gave the stock a "buy" rating in a research note on Monday.March 18, 2024 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Large Decline in Short InterestAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) was the recipient of a significant drop in short interest in the month of February. As of February 29th, there was short interest totalling 1,810,000 shares, a drop of 9.0% from the February 14th total of 1,990,000 shares. Based on an average daily trading volume, of 1,350,000 shares, the short-interest ratio is presently 1.3 days.March 15, 2024 | msn.com5 Growth Stocks Under $50 for March 2024March 15, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Allogene Therapeutics (ALLO), Aquestive Therapeutics (AQST) and Allakos (ALLK)March 14, 2024 | globenewswire.comAquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA MeetingMarch 13, 2024 | insidertrades.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Insider Alexander Mark Schobel Sells 25,000 SharesMarch 12, 2024 | finance.yahoo.comInsider Sell: Chief Innovation/Tech Officer Alexander Schobel Sells 25,000 Shares of Aquestive ...March 12, 2024 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Insider Sells $129,750.00 in StockAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) insider Alexander Mark Schobel sold 25,000 shares of the company's stock in a transaction on Friday, March 8th. The shares were sold at an average price of $5.19, for a total transaction of $129,750.00. Following the completion of the transaction, the insider now owns 1,040,371 shares of the company's stock, valued at approximately $5,399,525.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Former Wingman Bets Big on AI (Ad)One of his AI company’s earliest investors was the CIA’s venture capital arm called In-Q-Tel … named after Q, the fictional character who makes gadgets for James Bond. Soon, an alphabet soup of 30 government agencies would entrust the company with their most sensitive information. Get the full story here. AQST Media Mentions By Week AQST Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AQST News Sentiment▼0.290.56▲Average Medical News Sentiment AQST News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AQST Articles This Week▼213▲AQST Articles Average Week Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PROC News NBTX News EPIX News FBLG News URGN News VNDA News NLTX News CRMD News ORGO News AKBA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AQST) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
